CRE/CPE/CRO: Demystifying the microbiology and opportunities for whole genome sequencing Jon Otter, PhD FRCPath Imperial College Healthcare NHS Trust 

Slides:



Advertisements
Similar presentations
1. 2 Global Travel – who goes? 3 Global Links of NDM to the UK Kumarasamy et al., Lancet Infect Dis :
Advertisements

Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal
Fred C. Tenover, Ph.D., D(ABMM) Vice President, Scientific Affairs
CRE Surveillance Activities
APIC Chapter 13 Journal Club April 15, 2015
Train-the-Trainer Interacting with your laboratory colleagues Customize this presentation with your organization’s logo, etc. 13/17/2014.
ANTIMICROBIAL RESISTANCE Edith Blondel-Hill MD,FRCP Medical Microbiologist/Infectious Diseases Specialist Medical Director Interior Health Antimicrobial.
FALL 2010 Course: Biology 225 Instructor: Dr. Janie Sigmon Hot Topics in Microbiology.
Recommendation on prudent use of antimicrobial agents in human medicine – Slovenian experiences Intersectoral Coordination Mechanism Prof. Milan Čižman,
© Aurora Health Care, Inc. Carbapenem Resistant Enterobacteriaceae The Alphabet Soup of Infection Prevention Aurora Health Care System Infection Prevention.
Moving forward together infection prevention and control and AMR Rose Gallagher Nurse Advisor Infection Prevention and Control Royal College of Nursing.
Division of Public Health CRE Surveillance and Prevention of Transmission in Healthcare Settings Gwen Borlaug, CIC, MPH Coordinator, Healthcare-Associated.
What’s happening now ? Epidemiology of (carbapenem) resistance Neil Woodford HPA – AMRHAI - Colindale.
CARBAPENEM RESISTANT ENTEROBACTERIACEAE: RISK FACTORS AND ROLE OF EXTENDED CARE FACILITIES A. Makarem, MD; P. Alvarez, MD; T. Chou, MPH, CIC; M. Kulkarni,
Carbapenemase- Producing Carbapenem-Resistant Enterobacteriaceae Nicole Hearon, HAI Epidemiologist Surveillance and Investigation Division Indiana State.
Rising to the challenge of multidrug-resistant Gram-negative bacteria
Detecting CPE: time to throw away those agar plates?
European Centre for Disease Prevention and Control
30mm 10mm logo safe area 10mm logo safe area EDITING NOTES All copy must stay within the content limit guidelines. Any image added to a slide with text.
Development of a Real-Time PCR (RT-PCR) Assay for Carbapenemase Producing Bacteria including Enterobacteriaceae B. Mather, P. L. White, M. Wootton, R.
European approaches to MDR- GNR prevention and control Jon Otter, PhD FRCPath Imperial College Healthcare NHS Trust Blog:
Containing CRE spread Jon Otter, PhD FRCPath Scientific Director, Healthcare, Bioquell Research Fellow, King’s College London
30mm 10mm logo safe area 10mm logo safe area EDITING NOTES All copy must stay within the content limit guidelines. Any image added to a slide with text.
Part II High Priority Resistant Organisms. Healthcare Associated Infections NHSN Staphylococcus aureus (16%) 2.Enterococcus spp (14%) 3.Escherichia.
Jean B. Patel, PhD, D(ABMM) Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Disease Centers for Disease Control.
Point of Care Diagnostics for Hospital Acquired Infections (HAIs): Health Economics Perspective Detection & Identification of Infectious Agents (DIIA)
Outcomes of Carbapenem-Resistant K. pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies Gopi Patel, MD; Shirish Huprikar, MD;
CPE, CRE, CPO and CRABs! Jon Otter, PhD FRCPath Imperial College Hospitals NHS Trust Blog:
Healthcare-Associated Infections and Infection Control
Antimicrobial Resistance (AMR) and Prescribing
Carbapenem Resistant Enterobacteriaceae:
Current Status of Antimicrobial Resistance
Alison Holmes, Jonathan Otter
The growing dangers around CPE
CRE Surveillance and Prevention
Professor Alan Johnson Department of HCAI & AMR
Screening for CPE: sensitivity of serial admission screens
CPE screening: seek and ye shall find!
Rising to the challenge of multidrug-resistant Gram-negative bacteria
Who’s carrying CPE? Universal admission screening in London
Managing repeated screening for known CPE carriers: once positive always positive? Siddharth Mookerjee, Eleonora Dyakova, Frances Davies, Kathleen Bamford,
IPC – new, novel, and exciting
GNBSI Can we really halve GNBSIs? Jon Otter, PhD FRCPath
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London
Counting the cost of controlling an outbreak of CPE: an economic evaluation Jonathan A. Otter,1,2 Philip Burgess,3 Frances Davies,2 Siddharth Mookerjee,2.
Nine decades of antibiotics: how many years of antibiotic resistance?
The ‘bed location lottery’: the MDRO status of the prior bed occupant affects the risk of acquisition Jon Otter, PhD Scientific Director, Healthcare, Bioquell.
Promiscuous plasmids? Scaling infection control implications of horizontal spread of carbapenemase genes between species Siddharth Mookerjee, Frances Davies,
Using the Toolkit to build a CPE policy
Main modes of transmission CPE
Risk factors for carbapenem-resistant Enterobacteriaceae (CRE) carriage at the time of hospital admission Siddharth Mookerjee,1 Eleonora Dyakova,1 Frances.
Counting the cost and value of hospital cleaning and disinfection
Carbapenem-resistant Gram-negative bacteria
Changes to 10A NCAC 41A May 5, 2018.
The Use of Molecular Epidemiology and
Cost utility of alternative Carbapenemase
Overseas travel and antibiotic use are more important than community demographics or measures of social and material deprivation in predicting ESBL colonization.
SUPERBUGS: STRUMENTI DI INTERVENTO NELL’ERA POST-ANTIBIOTICA
AMR: a clinical perspective
CPE: coming to a hospital near you!
Promoting a Public Health Approach to Detecting and Containing Novel and Emergent Antibiotic Resistant Organisms Maroya Walters, PhD, ScM Division of Healthcare.
Detecting and managing CPE outbreaks: seek and you shall find
Hospital cleaning and disinfection: we can do better!
Healthcare-associated C. difficile infections: acquisition of C
Removal of sinks from ICU Patient rooms
The management of CPE outbreaks panel
Implementing innovation when financial times are hard
National Center for Emerging and Zoonotic Infectious Diseases
Before an outbreak - what to do after first MDR Gram-negatives enter your hospital? Jon Otter, PhD FRCPath Imperial College London
An introduction to infectious diseases epidemiology
Presentation transcript:

CRE/CPE/CRO: Demystifying the microbiology and opportunities for whole genome sequencing Jon Otter, PhD FRCPath Imperial College Healthcare NHS Trust Blog: You can download these slides from

MRSA bacteraemia, England Mandatory reporting, ‘Gettting ahead of the curve’, ‘Winning ways’, ‘Towards cleaner hospitals’, ‘Cleanyourhands’, Targets introduced, Cleanliness improvement, ‘Going further faster’, Root cause analysis, Revised national guidelines, Deep clean, Screening elective admissions, Universal screening,

CDI cases, C. difficile infection (CDI), England Mandatory reporting, Targets, Revised guidelines,

THE END OF ANTIBIOTICS IS NIGH

“CPE are nightmare bacteria.” Dr Tom Frieden, CDC Director “If we don't take action, then we may all be back in an almost 19th Century environment where infections kill us as a result of routine operations.” Dame Sally Davies, Chief Medical Officer “If we fail to act, we are looking at an almost unthinkable scenario where antibiotics no longer work and we are cast back into the dark ages of medicine where treatable infections and injuries will kill once again.” David Cameron, Prime Minister, UK “The rise of antibiotic-resistant bacteria, however, represents a serious threat to public health and the economy.” Barack Obama, President USA What’s the problem?

Rising threat from MDR-GNR % of all HAI caused by GNRs. Hidron et al. Infect Control Hosp Epidemiol 2008;29: Peleg & Hooper. N Engl J Med 2010;362: % of ICU HAI caused by GNRs. Non-fermentersAcinetobacter baumannii Pseudomonas aeruginosa Stenotrophomonas maltophilia EnterobacteriaceaeKlebsiella pneumoniae Escherichia coli Enterobacter cloacae CPE CPO

Poll: would you be comfortable explaining the difference between ‘carbapenem-resistant Enterobacteriaceae (CRE)’ and ‘carbapenemase producing Enterobacteriaceae (CPE)’ to a colleague? A) Yes B) No

Gimme a “C” (TLA overdose) CCarbapenem or Carbapenemase R or PResistant or Producing E or OEnterobacteriaceae or Organism CRO > CPO CRE > CPE > >

CRE or CPE (or possibly CP-CRE)?! Carbapenem-resistant Enterobacteriaceae (CRE) – Enterobacteriaceae that are resistant to carbapenems by any mechanism. Carbapenemase-producing Enterobacteriaceae (CPE) – Enterobacteriaceae that are resistant to carbapenems by means of an acquired carbapenemase. CRE CPE

When CRE is not CPE Courtesy of Dr Katie Hopkins, PHE. Carbapenem MIC N Wild-type Carbapenemase ESBL / AmpC + porin loss or true carbapenemase ?

Enterobacteriaceae ESBLs CPE Creating a monster Extended-spectrum beta-lactams Carbapenems

ShareDiffer Gram stain reactionRisk factors & at-risk population Concerning AMRPotential for epidemic spread Infection profile & mortality Prevalence Colonisation site & duration Transmission routes Resistance profile & mechanisms Enterobacteriaceae vs. non-fermenters

What’s the problem? Resistance Courtesy of Pat Cattini

EnterobacteriaceaeNon fermenters OrganismAmpC / ESBLCPEA. baumannii Attributable mortality ModerateMassive (>50%)Minimal Shorr et al. Crit Care Med 2009;37: Patel et al. Iinfect Control Hosp Epidemiol 2008;29: What’s the problem? Mortality

What’s the problem? Rapid spread Rapid spread Clonal expansion GI carriage Horizontal gene transfer

Acronym minefield MDR-GNR MDR-GNB CRO CPE CRE NDM CPC CRC CRAB ESBL KPC

Understanding the enemy PathogenCPE 1 CPAB 2 MRSAVREC. difficile Resistance /- Resistance genes Multiple Single n/a SpeciesMultipleSingle HA vs CAHA & CAHA (ICU)HA At-risk ptsAllICUUnwell Old Virulence++++/-+++/-+ Environment+/ Carbapenemase-producing Enterobacteriaceae. 2.Carbapenemase-producing Acinetobacter baumannii.

Poll: How much CPE have you seen in your hospital? A) None B) One or two cases C) One or two outbreaks D) Regularly (not related to known outbreaks)

NHSN / NNIS data; MMWR 2013;62: CRE in the USA

Colistin resistance in Italy Monaco et al. 2014; Euro Surveill 2014;19:pii= Survey of 191 CPE from 21 labs across Italy. 43% Colistin resistant K. pneumoniae. Range = 10-80% for the 21 labs.

Emergence of CPE in the UK PHE.

CPE in the UK and US

Evidence-free zone

CPE prevention & control Hand hygiene Cleaning / disinfection SDD?Topical CHX?Education? Contact precautions Active screening Antibiotic stewardship Otter et al. Clin Microbiol Infect 2015;21:

Rectal swab Agar plate AST MADLDI- TOF MS WGS NAAT (PCR) NAAT (PCR) How do I screen? NAAT = nucleic acid amplification techniques AST = antimicrobial susceptibility testing MALDI-TOF = Matrix-assisted laser desorption /ionization – time of flight mass spectrometry WGS = whole genome sequencing

NAAT direct from clinical specimens PCR Rapid real-time PCR kits available to detect resistance genes direct from clinical specimens; point of care tests coming Rapid sequencing kits Kits available for rapid sequence-based simultaneous detection of common organisms and resistance genes

WGS & enhanced epidemiology Possible transmissions links using conventional epidemiology only (left, aka “Plate of Spaghetti”) or supplemented with WGS data (right). Snitkin et al. Sci Transl Med 2012;4:148ra16.

Summary 1.MDR-GNR are emerging worldwide and represent a unique threat. 2.CPE in particular combine resistance, virulence and the potential for rapid spread. 3.Prevalence in the US and Europe appears to be patchy, but increasing; rates in parts of S. Europe are high. 4.We do not yet know what is effective in terms of prevention and control, but screening and isolation of carriers seems prudent. 5.Whole genome sequencing presents exciting opportunities to enhance the surveillance of CPE.

CRE/CPE/CRO: Demystifying the microbiology and opportunities for whole genome sequencing Jon Otter, PhD FRCPath Imperial College Healthcare NHS Trust Blog: You can download these slides from